• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接种疫苗是实现群体免疫的唯一可行途径。

Vaccination Is the Only Acceptable Path to Herd Immunity.

机构信息

Center for Global Health Science and Security, Georgetown University, Washington, DC 20057, USA.

出版信息

Med. 2020 Dec 18;1(1):21-23. doi: 10.1016/j.medj.2020.12.004.

DOI:10.1016/j.medj.2020.12.004
PMID:33521750
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7831753/
Abstract

Population-level herd immunity is critical for long-term control of SARS-CoV-2. However, proposals to reach the herd immunity threshold through naturally acquired infection, rather than vaccination, have complicated public health efforts and popularized policies that will lead to widespread transmission and mortality. Vaccination is the only viable path to herd immunity.

摘要

人群层面的群体免疫对于长期控制 SARS-CoV-2 至关重要。然而,通过自然感染而不是接种疫苗来达到群体免疫阈值的建议使公共卫生工作变得复杂,并使可能导致广泛传播和死亡的政策得到普及。接种疫苗是实现群体免疫的唯一可行途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17c3/7831753/79915616ff74/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17c3/7831753/79915616ff74/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17c3/7831753/79915616ff74/gr1.jpg

相似文献

1
Vaccination Is the Only Acceptable Path to Herd Immunity.接种疫苗是实现群体免疫的唯一可行途径。
Med. 2020 Dec 18;1(1):21-23. doi: 10.1016/j.medj.2020.12.004.
2
Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile.引发 SARS-CoV-2 感染群体免疫的挑战:可能不可能但似乎有可能。
Infect Disord Drug Targets. 2022;22(4):e170122200309. doi: 10.2174/1871526522666220117153838.
3
The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant.接种疫苗诱导针对 SARS-CoV-2 B.1.1.7 变异株的群体免疫的潜力。
Euro Surveill. 2021 May;26(20). doi: 10.2807/1560-7917.ES.2021.26.20.2100428.
4
The devil in the details: Herd immunity and pandemic response.细节中的魔鬼:群体免疫与大流行应对。
Cell Host Microbe. 2021 Jul 14;29(7):1048-1051. doi: 10.1016/j.chom.2021.06.017.
5
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
6
Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases.微生物组的影响:针对病毒病不断发展群体免疫的范例。
Viruses. 2020 Oct 10;12(10):1150. doi: 10.3390/v12101150.
7
Impact of vaccination on the COVID-19 pandemic in U.S. states.疫苗接种对美国各州 COVID-19 大流行的影响。
Sci Rep. 2022 Jan 28;12(1):1554. doi: 10.1038/s41598-022-05498-z.
8
Herd immunity threshold for SARS-CoV-2 and vaccination effectiveness in Brazil.巴西SARS-CoV-2的群体免疫阈值及疫苗有效性
J Bras Pneumol. 2022 May 30;48(2):e20210401. doi: 10.36416/1806-3756/e20210401.
9
[Review of the concept of herd immunity, in the context of COVID-19 epidemic and the development of vaccines].[在新冠疫情及疫苗研发背景下对群体免疫概念的综述]
Rev Chilena Infectol. 2021 Aug;38(4):495-499. doi: 10.4067/S0716-10182021000400495.
10
Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2.昆士兰州群体免疫需求建模:疫苗效力、犹豫和 SARS-CoV-2 变异的影响。
Philos Trans A Math Phys Eng Sci. 2022 Oct 3;380(2233):20210311. doi: 10.1098/rsta.2021.0311. Epub 2022 Aug 15.

引用本文的文献

1
Utilizing virus genomic surveillance to predict vaccine effectiveness.利用病毒基因组监测来预测疫苗效果。
medRxiv. 2025 Jun 22:2025.06.20.25329795. doi: 10.1101/2025.06.20.25329795.
2
Scrutinizing the COVID-19 vaccine safety debate.审视新冠疫苗安全性辩论。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2401646. doi: 10.1080/21645515.2024.2401646. Epub 2024 Oct 29.
3
Medical Ethics and Informed Consent to Treatment: Past, Present and Future.医学伦理与治疗知情同意:过去、现在与未来

本文引用的文献

1
Herd Immunity and Implications for SARS-CoV-2 Control.群体免疫及其对新冠病毒控制的影响。
JAMA. 2020 Nov 24;324(20):2095-2096. doi: 10.1001/jama.2020.20892.
2
A systematic review of SARS-CoV-2 vaccine candidates.SARS-CoV-2 疫苗候选物的系统评价。
Signal Transduct Target Ther. 2020 Oct 13;5(1):237. doi: 10.1038/s41392-020-00352-y.
3
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Cureus. 2024 Dec 9;16(12):e75377. doi: 10.7759/cureus.75377. eCollection 2024 Dec.
4
Parental hesitancy against COVID-19 vaccination for children and associated factors in Taiwan.台湾地区父母对儿童 COVID-19 疫苗接种的犹豫及其相关因素。
BMC Public Health. 2023 Mar 27;23(1):571. doi: 10.1186/s12889-023-15158-0.
5
Factors Associated with COVID-19 Vaccination Acceptance Among Muslim High School Students in Jakarta Metropolitan Area, Indonesia.印度尼西亚雅加达都会区穆斯林高中生中与新冠疫苗接种接受度相关的因素
J Multidiscip Healthc. 2022 Oct 14;15:2341-2352. doi: 10.2147/JMDH.S380171. eCollection 2022.
6
Understanding the Role of Environmental Transmission on COVID-19 Herd Immunity and Invasion Potential.理解环境传播在 COVID-19 群体免疫和入侵潜力中的作用。
Bull Math Biol. 2022 Sep 10;84(10):116. doi: 10.1007/s11538-022-01070-y.
7
COVID-19 vaccine hesitancy among health care worker-parents (HCWP) in Puducherry, India and its implications on their children: A cross sectional descriptive study.印度本地治里医护人员家长(HCWP)对 COVID-19 疫苗的犹豫及其对子女的影响:一项横断面描述性研究。
Vaccine. 2022 Sep 22;40(40):5821-5827. doi: 10.1016/j.vaccine.2022.08.051. Epub 2022 Aug 29.
8
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.COVID-19 鼻内疫苗:当前进展、优势、前景和挑战。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2045853. doi: 10.1080/21645515.2022.2045853. Epub 2022 Mar 8.
9
Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein.SARS-CoV-2 刺突蛋白的结构动力学和分子进化。
mBio. 2022 Apr 26;13(2):e0203021. doi: 10.1128/mbio.02030-21. Epub 2022 Mar 8.
10
Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.初次感染和既往感染新冠病毒个体对SARS-CoV-2感染及疫苗接种的抗体反应
Viruses. 2022 Feb 10;14(2):370. doi: 10.3390/v14020370.
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
4
A history of herd immunity.群体免疫史。
Lancet. 2020 Sep 19;396(10254):810-811. doi: 10.1016/S0140-6736(20)31924-3.
5
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.冠状病毒抗体介导免疫的系统评价:动力学、保护相关性及与严重程度的关系。
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
6
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.新冠病毒(COVID-19)中 Bcl-6 表达的滤泡辅助性 T 细胞和生发中心的缺失。
Cell. 2020 Oct 1;183(1):143-157.e13. doi: 10.1016/j.cell.2020.08.025. Epub 2020 Aug 19.
7
Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.2020年3月23日至5月12日美国10个地点针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗体的血清流行率
JAMA Intern Med. 2020 Jul 21. doi: 10.1001/jamainternmed.2020.4130.
8
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。
Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.
9
Lymphopenia during the COVID-19 infection: What it shows and what can be learned.新冠病毒感染期间的淋巴细胞减少症:所呈现的情况及可从中了解到的信息。
Immunol Lett. 2020 Sep;225:31-32. doi: 10.1016/j.imlet.2020.06.013. Epub 2020 Jun 20.
10
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.宿主对 SARS-CoV-2 的失衡反应导致 COVID-19 的发生。
Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026. Epub 2020 May 15.